Bariatric surgery lowers retinopathy rates

Bariatric surgery is back in the obesity-treatment conversation for a reason. The new angle is the eye — specifically diabetic retinopathy, one of the most common ways diabetes damages vision. At the ASMBS meeting on May 6, UVA Health researchers said older adults with obesity and diabetes had lower 5-year retinopathy rates after metabolic surgery than after GLP-1 treatment. The result wasn’t just about eyesight, either — it lined up with lower heart and kidney complication rates too. ### What changed here? The fresh news is a real-world comparison focused on adults age 65 and older. Researchers used Epic’s Cosmos database, looked at patients treated from 2017 to 2025, and compared people who had sleeve gastrectomy or gastric bypass with people taking GLP-1 drugs including semaglutide, dulaglutide, or tirzepatide. After matching patients with similar baseline traits, the analysis covered more than 107,000 people. ### What was the eye result? After 5 years, diabetic retinopathy occurred in 5.8% of the surgery group and 9.0% of the GLP-1 group — a relative drop of about 35%. In the same analysis, major cardiovascular events were 11.5% after surgery versus 13.6% with GLP-1s, and severe kidney disease was 9.1% versus 12.4%. So the eye finding wasn’t an isolated blip — it sat inside a broader pattern of fewer diabetes-related complications. ### Why would surgery help the eyes? Basically, retinopathy tracks long-term metabolic stress. Better blood sugar helps, but it’s not the whole story. In this study, HbA1c improved similarly in both groups, while weight loss separated sharply — 17.3% in the first year after surgery versus 4.2% with GLP-1 therapy — all of which can feed retinal damage over time. That last part is an inference, but it fits the pattern in the data. ### Is this a one-off result? Not really. A Cleveland Clinic study published in *Nature Medicine* in September 2025 found the same general direction in a different population — adults with obesity and type 2 diabetes followed for up to 10 years. In that study, metabolic surgery was linked to a 54% lower risk of diabetes-related eye damage than GLP-1 medicines, along with lower risks of death, major heart problems, and serious kidney disease. ### Does that mean GLP-1 drugs are bad for the eyes? No. That would be too strong. GLP-1 drugs clearly help with diabetes and obesity, and they improve cardiovascular and metabolic health. The more accurate read is that surgery may deliver larger and longer-lasting systemic effects. It is a different question from these longer-term outcome comparisons. ### So should surgery replace GLP-1s? No — and the researchers themselves are not framing it that way. The practical point is that surgery should not be treated as a last-resort relic from the pre-GLP-1 era. Mayo Clinic researchers said something similar in April 2026: both treatments help, but surgery was associated with bigger long-term cardiovascular risk reduction, largely because the weight loss was larger and more sustained. ### What’s the catch? This older-adult result was presented at a conference, not yet published as a full peer-reviewed paper, and it comes from observational data rather than a randomized trial. That means matching can reduce bias, but it can’t erase it. People who undergo surgery may differ from medication users in ways databases only partly capture. ### Bottom line? The interesting part is not “surgery beats drugs” as a slogan. It’s that the retina — a tiny, fragile blood-vessel network — seems to be reflecting the same whole-body advantage seen in the heart and kidneys. If that signal holds up, the obesity-treatment debate gets a lot less cosmetic and a lot more about preventing blindness and organ damage.